Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage biotechnology leader developing novel stem cell-based delivery systems for oncolytic virotherapies. This page provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in cancer treatment innovation.
Access comprehensive coverage of CLDI's progress across its therapeutic platforms, including CLD-101 for high-grade gliomas and RTNova for metastatic cancers. Our curated news collection features verified updates on trial milestones, regulatory filings, and peer-reviewed research findings essential for understanding the company's trajectory.
Key updates include developments in Phase 1b/2 clinical trials, technology licensing agreements, and advancements in systemic virotherapy delivery systems. All content undergoes rigorous verification to ensure accuracy in reporting complex biopharmaceutical developments.
Bookmark this page for streamlined access to Calidi's latest press releases, investor communications, and analysis of its stem cell platform's potential across oncology and regenerative medicine applications. Stay informed about critical developments in next-generation cancer therapies through our maintained news repository.
Calidi Biotherapeutics (NYSE American: CLDI) is developing a next-generation platform for cancer treatment using engineered viruses to deliver genetic medicines directly to tumors. The company's innovative approach targets both primary and metastatic tumors, addressing a critical healthcare need as cancer diagnoses are projected to reach 35 million annually by 2050.
While initially focused on oncology, Calidi is also exploring applications in autoimmune disorders. This development comes as global cancer cases reach 20 million diagnoses and 10 million deaths annually, highlighting the urgent need for more effective treatment options.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, has secured approximately $4.6 million in gross proceeds through the exercise of multiple series of warrants. The agreement involves the immediate exercise of Series A, B-1, C-1, D, E, and F warrants for 6,595,000 shares at a reduced price of $0.70 per share.
In exchange for the immediate cash exercise, Calidi will issue new unregistered warrants to purchase up to 6,595,000 shares at $0.70 per share, exercisable after six months with a 5.5-year term. The proceeds will support clinical and pre-clinical programs, operating expenses, and working capital. Ladenburg Thalmann & Co. is serving as the exclusive placement agent.
Calidi Biotherapeutics (NYSE American: CLDI) is developing a precision genetic medicine platform for cancer treatment. The company's innovative approach focuses on using engineered viruses to deliver genetic medicines that can target both primary tumors and metastatic sites.
The development comes amid concerning cancer statistics, with 20 million annual cancer diagnoses globally and projections showing this number could reach 35 million by 2050. Currently, cancer claims nearly 10 million lives annually worldwide, highlighting the urgent need for more effective treatment options.
Calidi Biotherapeutics (NYSE American: CLDI) issued a shareholder letter highlighting significant company developments under new CEO Eric Poma. The company's primary focus is advancing their RedTail platform, a systemic virotherapy platform for delivering genetic medicines to metastatic cancer sites.
Key developments include the appointment of Dr. Guy Travis Clifton as CMO, positive preclinical data presentations at AACR and ASCO meetings, and plans for an IND filing by end of 2026 for CLD-401, their lead RedTail candidate. The company also opened an IND for SuperNova virotherapy (CLD-201) with phase I trials expected to start by end of 2025.
Financially, Calidi reported $10.6 million in cash at Q1 2025 end, with reduced costs and lower burn rate. The company has retired most of its debt and is exploring partnership opportunities with leading biopharmaceutical companies.
Calidi Biotherapeutics (NYSE: CLDI) has announced IL15 superagonist as the first payload for its systemic antitumor virotherapy platform, RTNova. The announcement was made at the AACR Annual Meeting on April 27, 2025.
The RTNova platform utilizes an engineered vaccinia virus designed for tumor-selective targeting and produced in an enveloped form that enables survival in bloodstream circulation to reach metastatic tumor sites. Preclinical data demonstrates that the platform's ability to express IL15 superagonist specifically in tumor microenvironments significantly increases complete tumor elimination responses after a single systemic administration.
This advancement represents a significant step in treating metastatic cancers, as it overcomes the limitations of traditional intratumoral oncolytic viruses by enabling systemic administration. The platform can also be adapted to deliver various therapeutic payloads, allowing customized treatment approaches for different tumor types.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has granted an inducement non-qualified stock option to its newly appointed CEO, Eric Poma, Ph.D. The stock option allows for the purchase of 726,412 shares at an exercise price of $0.469 per share, based on the closing price on April 22, 2025.
The stock options feature a four-year vesting schedule, with 25% vesting on April 22, 2026, and the remaining portion vesting in equal monthly installments through April 22, 2029. This grant was approved by the Company's Compensation Committee and Board of Directors in accordance with Section 711 of NYSE American Company Guide.
Calidi Biotherapeutics (NYSE American: CLDI) has announced a significant leadership transition, with Eric Poma, Ph.D. succeeding Allan Camaisa as CEO and Board Director, effective April 22, 2025. Camaisa will remain on the Board.
Dr. Poma brings over 30 years of biopharmaceutical industry experience, notably as CEO of Molecular Templates where he raised $250+ million in equity financing and secured $150+ million through strategic agreements with Takeda, Vertex, and BMS. His background includes roles at Innovive Pharmaceuticals, Imclone Systems, and as a Healthcare & Biotechnology Analyst.
The transition comes as Calidi, a clinical-stage biotechnology company, advances its systemic enveloped virotherapy platform, including preparations for a dose escalation trial of CLD-201 in adult patients with solid tumors. The company continues development of its CLD-400, CLD-101, and CLD-201 programs.
Calidi Biotherapeutics (NYSE American: CLDI) announces an exclusive live investor webinar scheduled for April 24, 2025, at 4:15 p.m. ET. The event will feature presentations by newly appointed Chief Medical Officer Dr. Guy Travis Clifton and CFO Andrew Jackson.
Dr. Clifton, a surgical oncologist and U.S. Army Colonel with 17 years of experience in oncology drug development, will discuss Calidi's stem cell-based delivery platforms for enhanced cancer treatment. The webinar will highlight the company's progression following FDA clearance of their IND application for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, focusing on breast cancer, head & neck cancer, and soft tissue sarcoma.
The presentation will also cover other lead programs including CLD-400 (RTNova) for metastatic and lung cancer, and CLD-101 for high-grade gliomas. A Q&A session will follow the presentation.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
